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ABSTRACT 
Protein mis-folding and aggregation result in many human diseases and some of these diseases are 
caused when the protein aggregation leads to amyloid formation (Chiti and Dobson, 2006). Amyloids 
are insoluble, fibrous and well organized protein aggregates having cross-β core structure (Chiti and 
Dobson, 2006, Nelson et al., 2005). Some of the examples of amyloid-associated diseases include: 
Alzheimer’s disease, Prion disease, and Huntington’s disease. The all-α helix, acidic and multi-
domain proteins bovine serum albumin (BSA) and Human serum albumin (HSA) can also form 
amyloid aggregates in vitro at high temperatures (Holm et al., 2007, Juarez et al., 2009a). BSA and 
HSA have multi-functional in vivo roles like delivering major nutrients to the cells and isolating toxins 
from the cells as they possess many ligand binding sites. They have half-life of 19 days and ability to 
restore plasma (Wunder et al., 2003). These proteins have one free cysteine and share over 76% 
sequence similarity (Francis, 2010) ( Huang et al., 2004). Recently, these proteins have been used as 
a plasma expander and also as preferred drug delivery agents (Park, 2012). Amyloid aggregates can 
be either cytotoxic causing disease or they can be beneficial or functional in some cases. BSA/HSA 
amyloid aggregates are shown to be non-cytotoxic (Holm et al., 2007) and are not involved in 
causing amyloid diseases, thus a better understanding of their amyloid properties can help in finding 
any potential applications. The present work undertakes a comparative analysis of properties of BSA 
and HSA protein amyloid aggregates. It is found here that despite the very high sequence similarity 
and similar biochemical properties, the amyloid aggregates of BSA and HSA vary significantly in their 
properties and stabilities. Previously, conjugation of therapeutic proteins (eg. Interferon alfa 2b & 
human growth hormone) with HSA has been shown to increase their circulatory life span and hence 
their therapeutic period. Here, we hypothesized that conjugating a therapeutic protein or peptide to 
amyloid form of HSA would further extend the circulatory life as the amyloid clearance is expectedly 
slower.  As a proof of the feasibility, we succeeded in cross-linking two HSA molecules via their one 
free-cysteine residues followed by converting them into amyloid-like aggregates. Further studies 
using amyloid converted heterodimer of HSA with a therapeutic protein could lead to potential 
applications if the hetero-dimer aggregates remain non-cytotoxic.  
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Abbreviations 
BSA     Bovine serum albumin 
HSA    Human serum albumin 
SDS   Sodium dodecyl sulphate 
Sarkosyl  Sodium lauroyl sarcosinate 
RT                  Room temperature 
R                    Reducing condition 
NR                 Non-reducing condition 
SDD-AGE     Semi-denaturing detergent agarose gel electrophoresis  
SDS-PAGE   Sodium dodecyl sulphate-polyacrylamide gel electrophoresis  
DTNB                     5, 5’-dithio-bis (2-nitrobenzoic acid) 
DTT   Dithiothreitol 
Th-T   Thioflavin-T  
CR   Congo red 
NaCl   Sodium chloride 
H2O2    Hydrogen peroxide 
EPR    Enhanced permeability and retention effect 
SEC   Size exclusion chromatography 
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 CHAPTER I 
INTRODUCTION        
1.1 Amyloid aggregates 
Many human diseases are as a result of protein misfolding and aggregation. Some of these diseases 
are caused due to protein aggregation in an amyloid form (Chiti and Dobson, 2006). Amyloids are 
unbranched, fibrillar, rigid, insoluble, highly organized and protease-resistant aggregates of 
proteins (Chiti and Dobson, 2006). These are approximately 75-100 Å in diameter.  
                                                
Figure 1: Typical morphology of amyloid fibrils observed under electron microscope (Sunde and 
Blake, 1997). 
They have characteristic “cross β-sheet” structure, revealed by X-ray diffraction studies, where the 
β-sheets are parallel to the axis of the fibril but -strands are perpendicular to the fiber axis and 
hence the name cross- (Nelson et al., 2005) (Figure 2). 
 
 
 
 
 
 
 
 
                        Figure 2:  Cross-beta structure present in amyloids (Nelson et al., 2005). 
Amyloids differ from other fibrillar structures like collagen or silk fibroin in their ability to bind the 
dye Congo red and exhibit bright apple green birefringence when viewed under polarized light 
(Figure 3), and also in their ability to bind the dye Thioflavin T thereby exhibiting bright fluorescence 
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(Figure 4) (LeVine, 1993). Amyloid aggregates are partially stable against protease (eg. proteinase K) 
and even ionic detergents like SDS and sodium lauroyl sarcosinate at room temperature. 
(a) (b)                                            (b)                                                 
 
 
   
  
        Figure 3: (a) Red in Bright field microscopy (b) Bright apple green birefringence in Polarized light      
microscopy (Merlini and Bellotti, 2003). 
 
 
 
 
  
 
             Figure 4: Characteristic increase in ThT fluorescence upon binding to amyloid fibrils. 
Amyloid formation is a nucleation dependent process (Figure 5a & b). The rate of growth of amyloid 
fibres is increased by the presence of even small amounts of pre-formed aggregates which act as 
seed. This process is known as seeding (Figure 6) and it bears resemblance to crystal growth of 
proteins or salts which can also be seeded by pre-formed crystals.  
 
                                
                                                   Figure 5: (a) Schematic of Amyloid aggregation. 
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Figure 5: (B) Amyloid formation by nucleation dependent polymerization mechanism (Sunde 
and Blake, 1997).  
 
                                             
Figure 6: Nucleation-dependent polymerization model of amyloid aggregation (Kumar and 
Walter, 2011). 
 
As expected, the process of seeding leads to reduction in the lag period preceding the amyloid 
growth and thus the amyloid growth curve shift toward left of the unseeded growth curve. 
1.2 Amyloidosis 
Amyloidosis is a pathological state associated with the deposition of conformationally altered 
proteins in the amyloid state, generally in the extracellular spaces of organs or tissues  (Pepys, 2006) 
(called plaques or amyloid fibrils) but also sometimes as intracellular “inclusions bodies”. The most 
well-known neurodegenerative disease caused due to amyloid deposits is the Alzheimer’s disease 
where the deposition of Aβ 1-40 peptide fragments happens in brain. Parkinson’s and Huntington’s 
diseases are also amyloid diseases and are caused by the aggregation of α-synuclein and huntingtin 
protein respectively (Chiti and Dobson, 2006).                             
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Amyloid deposition can be in a systemic or localized pattern. When the amyloid is restricted to a 
particular organ or tissue, it is called a localized amyloidosis. When the amyloid depositions are 
found in many or all of the body regions the disease is a called systemic amyloidosis. Amyloid 
deposition can occur in organs such as kidneys, spleen, heart, muscles, brain or even blood vessels.    
Furthermore, amyloidosis can be familial (hereditary) or acquired. Acquired amyloid disease can 
develops due to the aggravation of an already present diseased state in an individual, whereby there 
is an increase in the amount of proteins with amyloid characteristics. Example- secondary reactive 
amyloidosis, which occurs due to aggregation of the serum amyloid A protein, secreted during acute 
phase inflammation arising as a result of a primary disease conditions, like rheumatoid arthritis or 
tuberculosis (Merlini and Bellotti, 2003). Hereditary or familial amyloidosis occur due to the 
deposition of an altered protein encoded by a mutated gene. Example- Fibrinogen amyloidosis 
occurs due to mutations in the fifth exon region of the fibrinogen α chain encoding gene (Kang et al., 
2005). 
Amyloid aggregates can become cytotoxic by permeabilizing the cell membrane thereby leading 
to increase in cytosolic free calcium (Ca2+ dyshomeostasis) (Demuro et al., 2005). The increase in 
Ca2+ level in mitochondrial matrix results in reactive oxygen species production, cytochrome c 
release, altered signalling pathway, and finally mitochondria dysfunction occurs. Amyloidosis can 
be also grouped into neurodegenerative amyloidosis, non-neuropathic localized amyloidosis and 
non-neuropathic systemic amyloidosis (Chiti and Dobson, 2006). In neurodegenerative amyloidosis, 
aggregation occurs in the brain as found in Alzheimer’s disease, Parkinson’s disease and 
Huntington’s disease. In non-neuropathic localized amyloidosis, aggregation occurs in a single type 
of tissue as in the case of AL amyloidosis. In non-neuropathic systemic amyloidosis, aggregation 
occurs in multiple tissues as found to be in atrial amyloidosis, pulmonary alveolar proteinosis, and 
fibrinogen amyloidosis. (Chiti and Dobson, 2006). List of Amyloid associated diseases is given in 
Table 1. 
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              Table 1: List of amyloid associated diseases (Chiti and Dobson, 2006). 
 
1.3 Functional amyloid aggregates 
Formation of amyloid structure has been hypothesized as an inherent or generic property of every 
polypeptide chain (Polverino de Laureto et al., 2003). All Amyloids are not cytotoxic and some 
amyloid like structures are also present naturally which do not cause diseases. In fact, some 
amyloids are called “functional amyloids” as they may have beneficial role. For example: The  E.coli 
have a protein called curlin which forms amyloid structures and helps the organism to colonize on 
inert surfaces and mediate binding to host proteins. Also, the fungus Neurospora crassa secrete 
hydrophobins which are amyloid forming proteins that lower the water surface tension and allow 
the development of aerial hyphae. Furthermore, the silk fibers of the spider web are amyloid 
structures of the protein spidroin (Chiti and Dobson, 2006). Some other functional amyloids include: 
chaplins (Streptomyces coelicolor), hydrophobin EAS (Neurospora crassa), proteins of chorion of the 
eggshell (Bombyx mori), intralumenal domain of Pmel17 (Homo sapiens), Ure2p (Saccharomyces 
cerevisiae), Sup35p (Saccharomyces cerevisiae), Rnq1p (Saccharomyces cerevisiae), HET-s 
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(Podospora anserina) and neuron-specific isoform of CPBE (Aplisia californica) (Chiti and Dobson, 
2006). 
1.4. Amyloid aggregate forming proteins  
Amyloid formation may be an intrinsic property of most proteins and not just of those involved in 
disease states (Polverino de Laureto et al., 2003). The SH3 domain which is found in many proteins 
was shown to rapidly form amyloid fibrils thus initiating the hypothesis that probably the capability 
to form amyloid is more widespread among proteins. Thus in addition to the disease associated 
amyloid forming proteins (for e.g. Huntingtin, Alpha-synuclein, Aβ peptide and Lysozyme etc) 
several non-disease associated amyloid-forming proteins (e.g. BSA, HSA, Sup35 and Curlin etc) have 
been identified and studied. Non-disease amyloid forming proteins have been used as a model 
system to understand: 1. General mechanism of formation of amyloid (Bhattacharya et al., 2011). 2. 
Amyloid cross-seeding e.g. study of crossing of species barrier by : (a) sup35 prion protein between 
S. cerevisiae and C. albicans (Vishveshwara and Liebman, 2009). (b) cow prions are infectious to 
humans causing vCJD disease (Zou and Gambetti, 2009). 3. Potential application as structural nano-
materials (Cherny and Gazit, 2008); 4. The propagation of amyloid and prion e.g. sup 35 is used to 
study the infection mechanism of prion (Tanaka et al., 2005) 5. Potential application as drug 
delivery agent; eg. Insulin amyloid aggregates as potential sustained insulin delivery tool for 
diabetes treatment (Gupta et al., 2010). 
1.4.1. BSA and HSA: Model amyloid aggregate forming proteinsSerum Albumin 
Serum albumin is a globular protein and most abundant protein in blood plasma and it is present in 
the all mammals at a high concentration of 5g/100ml in blood. It transports important nutrients to 
the cells and also isolates toxins from the cells. It serves as a carrier protein for a variety of 
compound, like fatty acids, amino acids, bile salts, metals, hormones, drugs and pharmaceuticals. It 
is also responsible for the maintenance of blood pH and osmotic pressure. Serum albumin is 
synthesized by the liver initially as a preproalbumin. Subsequently, removal of the signal peptide 
makes proalbumin which is further processed by the removal of six-residue propeptide from the new 
N-terminus. Then the albumin is released into circulation which possesses a half-life of about 19 
days (Holm et al., 2007). 
 
 
15 
 
Bovine Serum Albumin (BSA) and Human Serum Albumin (HSA) 
BSA is the serum albumin found in a biological subfamily Bovinae (domestic cattle, African buffalo, 
the water buffalo, the yak, and the four-horned antelopes etc) and HSA is the serum albumin 
present in human blood. These proteins are acidic, all alpha structured, highly soluble, multi-
domain and also show high structural stability. The Molecular weight of BSA and HSA are 66 KD and 
67 KD respectively. Both BSA and HSA are made of a single peptide chain of 583 and 585 amino 
acids respectively with one free sulfhydryl group (on Cysteine 34) and 17 intrachain disulfide bonds 
(Taguchi et al., 2012). The secondary structures of BSA and HSA molecules are composed of ~ 67% 
alpha-helix, no beta-sheet, 10% turn, and 23% extended chains. The 3-D structure of BSA is very 
similar to t h e  HSA, because the two proteins share over 76% sequence identity (Huang et al., 
2004). The heart-shaped serum albumin molecule consists of three homologous-helical domains (I, II, 
III). Each domain contains two subdomains (A and B) that share common structural motif (Figure 7). 
Each domain can be divided into 10 helical segments: for example, h1–h6 for the subdomain A and 
h7–h10 for the subdomain B (Satyajit Patra et al., 2012) (Sugio et al., 1999). Howerver, HSA contains 
one tryptophan residue (Trp 214) as opposed to  two Trp residues in (Trp 135 and Trp 214) BSA 
(Gelamo and Tabak, 2000). 
 
 
 
 
  
 
 
 
 
Figure 7: (a) A BSA model structure from homology modelling (Satyajit Patra et al., 2012). (b) 
Crystal structure of the HSA molecule. Each subdomain is marked with a different color (yellow for 
subdomain IA; green, Ibo; red, Ilia; magenta, Ibis; blue, Iliac; and cyan, Jib). N- and C-termini are 
marked as N and C, respectively. Arg117, Lys351 and Lys475, which may be binding sites for long-
chain fatty acids, are colored white (Sugio et al., 1999). 
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1.4.2 BSA and HSA form amyloid aggregates 
BSA and HSA molecules have been shown to form aggregates at elevated temperatures. Previous 
studies have confirmed that these thermal protein aggregates have amyloid properties (Militello et 
al., 2004) (Vetri et al., 2011). To confirm their amyloid nature Th-T dye binding assay, Congo red dye 
binding assay, electron microscopy and atomic force microscopy (Figure 8) etc have been 
previously performed (Holm et al., 2007, Juarez et al., 2009a). 
   Figure 8: AFM and TEM images of BSA (Vetri et al., 2011)  & HSA amyloid (Juarez et al., 2009b) 
1.4.3 Aggregation pathways of serum albumins 
BSA and HSA can form amyloid aggregates at low pH 3.0 (Gly-HCl buffer) or at physiological pH 7.4 
(Sodium phosphate buffer) but only at high temperature, 65°C.  
 
 
 
 
 
 
 
 
 
 
                          Figure 9: Sketch of BSA aggregation pathways (Vetri et al., 2011). 
As shown in figure 9, high temperature induces partial unfolding of the protein thereby exposing the 
reactive areas. Further, the pH of the solution determines the type of aggregate formation. If pH is 
close to the isoelectric point, it leads to the formation of amorphous aggregates due to lack of 
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electrostatic repulsion and non-specific interaction of hydrophobic nature. At pH away from the 
isoelectric point, β-rich aggregates are formed as the electrostatic repulsion slow down the process 
thereby favouring the reorganization of aggregates into ordered form. At intermediate pH, interplay 
between various mechanisms may occur. 
 
HSA has been used as a plasma expander and its administration is considered to be helpful in the 
treatment of severe hypoalbuminemia during burns, nephritic syndrome, chronic liver cirrhosis and 
haemorrhagic shock (Taguchi et al., 2012). Furthermore, the homodimer of HSA is found to more 
potent than monomers as a plasma expander and drug carrier. Some of the examples of 
shortcomings of monomers are: 1. during many pathological and physiological conditions there is 
increase in the capillary permeability therefore, accumulation of albumin occurs in the extravascular 
compartment causing oedema leading to the worsening of the disease condition. 2. In nephritic 
syndrome, loss of HSA monomer takes place easily due to damaged glomerulus. 3. Enhanced 
permeability and retention (EPR) effect of HSA monomer is less than its dimer. These shortcomings 
can be overcome by using HSA dimer in place of HSA monomer which has higher molecular weight. 
Expectedly, during increase capillary permeability, HSA dimer maintains its concentration in the 
blood and the loss of albumin via kidney is also reduced. And EPR effect is also increased in case of 
HSA dimer due to increase in molecular weight and increase uptake of albumin in the solid tumours 
(Taguchi et al., 2012). Since amyloid form of a HSA homodimer would have even higher molecular 
weight, it may possibly be an even better albumin substitute. Furthermore, even after dissolution of 
the amyloid, it would release dimer molecules which do not cross the vasculature as easily as the 
monomer HSA does.  In addition, if the circulatory life of HSA conjugated with a therapeutic protein 
needs to be increased further, probably, using amyloid converted form of the HSA-therapeutic 
protein heterodimer may be of help provided it is non-cytotoxic. In the view of the above two 
possible applications, here we attempted to make homodimer of HSA and convert it into amyloid 
form. 
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CHAPTER II 
   MATERIALS AND METHODS  
  
2.1 Materials 
Bovine serum albumin (BSA) (product number A5611), Human serum albumin (HSA) (product 
number A6608), Congo red (CR), Thioflavin T (ThT), N-Lauroylsarcosine sodium salt (Sarkosyl), 
Sodium dodecyl sulphate (SDS), 5, 5’-DITHIO-BIS (2-NITROBENZOIC ACID) (Ellman’s reagent) were 
purchased from Sigma-Aldrich. Sodium chloride, Sodium phosphate dibasic and monobasic were 
purchased from Himedia. All other chemicals were also of high purity. 
 
2.2 Preparation of BSA and HSA protein amyloid aggregates  
BSA and HSA proteins were dissolved in 10mM sodium phosphate buffer pH 7.4 + 50mM NaCl to a 
final concentration of 10-20 mg/ml and incubated at 65°C in a water bath for 6 hrs and 52 hrs 
respectively without agitation (Holm et al., 2007, Juarez et al., 2009a). 
 
2.3 Confirmatory assays for Amyloid formation 
2.3.1 Thioflavin T dye binding assay 
First, 40μl of BSA aggregate sample was mixed with 2.6μl of ThT from a 30 mM stock solution. Th-T 
fluorescence emission intensity was measured in a Molecular Devices M5e Spectra Max Multimode 
microplate reader with excitation and emission wavelengths of 450 and 485nm respectively. 
Excitation spectrum was recorded by scanning the excitation wavelength from 250 nm to 470 nm 
and detecting emission at 495 nm. For emission spectrum, excitation wavelength was fixed at 
450nm and emission was scanned from wavelength 460nm to 560nm (LeVine, 1993). 
 
2.3.2 Congo red dye binding assay 
   HSA and BSA aggregates were added with Congo red dye dissolved in phosphate buffered saline, pH 
7.4 in 1:1 (150µM) molar ratio and the mixture was incubated for 30 min at RT. Subsequently,  
absorbance spectrum was measured from 250nm to 700nm in Molecular Devices M5e Spectra Max 
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Multimode microplate reader (Holm et al., 2007) (Hawe et al., 2008).  Increase in the absorbance 
value at 540 nm or generation of a shoulder peak at 540 nm was interpreted as amyloid-like 
successful Congo red binding. 
 
  2.3.3 Intrinsic tryptophan fluorescence 
  Intrinsic fluorescence of Tryptophan residues is a good parameter to study folding and unfolding of a 
protein (Vivian and Callis, 2001). When amyloid formation occurs, Trp residues present on the 
surface (hence in hydrophilic micro-environment) of the native protein may be expected to get 
internalized (hence in hydrophobic micro-environment) leading to change in the Trp fluorescence 
emission pattern. Thus, Trp fluorescence emission spectra was recorded (excitation wavelength at 
292nm; emission scan 300-400nm) to study HSA/BSA amyloid formation as these molecules contain 
surface Trp residues in their native conformation (Wang et al., 2010). 
 
2.3.4 Test for self-seeding of BSA /HSA amyloid aggregates   
Amyloid aggregates are ordered structures and display striking ability of self-seeding whereby the 
pre-formed aggregates recruit the un-aggregated monomers of the same molecule and convert 
them also into amyloid aggregates. Amyloid seeding was monitored using Molecular Devices M5e 
Spectra Max Multimode microplate reader and Thioflavin T fluorescence was used to track the 
amyloid formation. 5% pre-formed seed was added to the monomeric protein and amyloid 
conversion of the monomeric protein was assayed. The excitation wavelength was set at 450nm and 
the emission wavelength at 485nm. The rate of aggregation was monitored for a duration of 99hrs. 
 
2.4. Amyloid stability assays 
2.4.1 Comparison of detergent stability of BSA and HSA amyloid aggregates  
The analysis of molecular sizes of amyloid aggregates and their detergent insolubility was done by 
Semi-denaturing detergent-agarose gel electrophoresis (SDD-AGE) (Halfmann and Lindquist, 2008). 
Firstly, 1.5% agarose gel containing 0.1% SDS was prepared and BSA monomer (80 µg), HSA 
monomer (70 µg), BSA amyloid aggregates (200 µg) and HSA amyloid aggregates (240 µg) were 
loaded using a sample buffer containing 1% Sarkosyl in place of SDS. Samples were pre-incubated for 
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10 minutes at RT before electrophoresis. After electrophoresis, the samples were electro-blotted to 
a PVDF membrane for three hours and the membrane was subsequently stained with staining 
solution containing Coomassie R-250 dye. The molecular sizes of the amyloid aggregates was 
calculated by generating a calibration curve using relative mobility of marker proteins.  
 
2.4.2 Comparative pH stability of BSA and HSA amyloid aggregates  
BSA and HSA amyloid  aggregates were equilibrated at different pH (20mM Gly-HCl buffer pH 2.0; 
20Mm Sodium acetate-acetic acid buffer pH 4.0; 20mM Sodium-phosphate buffer pH 6.0; 20mM 
Tris-HCl pH 8.0; or 20mM Glycine-sodium hydroxide pH 10.0) for determining their relative pH 
stabilities. Thioflavin-T was added to the samples and its fluorescence was measured to estimate the 
residual amyloid and hence the residual stability.  
 
2.4.3 Comparative stability of BSA and HSA amyloid aggregates at pH6.0 and 40°C 
It is known that tumour cells have low pH due to increase in production of lactic acid and high 
temperature due to increase in their metabolic rates. In fact, the cytotoxicity of some anti-cancerous 
drugs is also increased at lower pH (pH 6.0) and higher temperature (40°C) (Hahn and Shiu, 1983). 
Possibly, amyloid aggregates could  be used to carry anti-cancerous drugs as amyloid aggregates are 
relatively thermo-stable (Surmacz-Chwedoruk et al., 2014) (Arora et al., 2004). Therefore, the 
stability of amyloid aggregates formed at pH 7.4 (normal conditions) was compared with pH 6.0 at 
40°C. This was achieved by bringing down the pH of amyloid aggregates in pH 7.4 to pH 6.0 and 
increasing the incubation temperature to 40 °C. Then the samples were ultra-centrifuged for 35 mins 
at 30,000 rpm and 4°C in Beckman Coulter table top OptimaTM MAX-XP ultracentrifuge. The relative 
distribution of the amyloid aggregates between supernatant and pellet was assessed using 
Thioflavin T binding assay, Bradford assay and SDS-PAGE. It would be expected that dis-aggregation 
of the amyloid due to lack of its stability under a given condition would increase the protein content 
in the supernatant fractions. 
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    2.5. Disulphide linked conjugation using free cysteine to obtain homo-dimers of 
BSA/HSA  
 
2.5.1 Estimation of free Sulfhydryl group of BSA and HSA by Ellman’s reagent assay 
5,5'-dithiobis-(2-nitrobenzoic acid) (DTNB) also known as Ellman’s reagent was used to determine the 
number of free sulfhydryl group in HSA/BSA proteins (Ellman, 1959). Sulfhydryl groups may be 
quantitated by using the extinction coefficient of TNB released upon reaction with DTNB. Protein 
samples of BSA, HSA or lysozyme at 0.15mM concentration were mixed with DTNB (4mg/ml) in the 
reaction buffer (sodium phosphate buffer pH 8.0) and incubated for 15 minutes at RT and absorption 
was measured at 412nm. Subsequently, free –SH group content was calculated using the following 
equation. The reported molar absorptivity of TNB in this buffer system at 412nm is 14,150. Molar 
absorptivity, Ε, is defined as follows:  
E=A/bc (where, A = absorbance, b = path length in cm, c = concentration in moles/liter)  
Solving for concentration gives the following formula: c=A/bE.  
 
2.5.2 Induced disulphide linked dimerization of BSA and HSA using H2O2 
Hydrogen peroxide was used as an oxidising agent for the dimerization of the BSA and HSA and the 
formation of dimers was confirmed by SDS-PAGE. A final concentration of 25mM H2O2 was used for 
the oxidation reaction of 150 µM BSA (or 150µM HSA) to induce the formation of the disulphide 
bonds. The reaction was performed in 8M urea to ensure the accessibility of –SH group of the 
cysteine residues as they are located in ~10 Å deep crevice (hydrophobic pocket) in the native 
BSA/HSA molecules (Francis, 2010). 
 
2.5.3 Purification of the homo-dimers of HSA/BSA by size exclusion chromatography  
As the H2O2 induced dimerization of both BSA and HSA was not 100% therefore, the dimers needed to 
be separated from the monomers for analysis of their amyloid formation ability. Using gel column 
chromatography (Superose 6, 10/300 GL and exclusion limit is 4x107), FPLC (ÄKTA™ FPLC™) system 
was performed to separate the dimes from the monomers which differ by ~ 66 kDa molecular 
weight. Monomers and dimers were present in a 50mM Gly-HCL + 150mM NaCl buffer pH 3.0 
(loading buffer) and 50mM Gly-HCL + 150mM NaCl buffer pH 3.0 was used for equilibration and 
elution. Briefly, 400µl of HSA conjugation reaction mixture containing 20 mg/ml of HSA proteins was 
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dialysed to remove the H2O2. After dialysis, the concentration of HSA was found to be 10 mg/ml and 
this mixture was loaded on to the SEC column for separation of the monomers and dimers. The 
elution of the proteins was monitored by absorption at 280 nm and fractions of 1ml and 250µl 
volume were collected in case of BSA and HSA respectively. The fractions containing protein were 
analysed by SDS-PAGE to detect the presence of monomer or dimer molecules. Those fractions 
containing dimers were pooled together and further used for amyloid formation. SEC purification of 
BSA dimers was also performed following the method described above for HSA dimer purification.  
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CHAPTER III 
RESULTS AND DISCUSSION 
  
3.1 In vitro formation of BSA and HSA protein amyloid aggregates 
     BSA and HSA proteins were dissolved in 10mM sodium phosphate buffer pH 7.4 containing 50mM 
NaCl at a concentration of 20 mg/ml. Fibrillization was induced by incubation without shaking at 
65°C for 6 hrs for BSA and 52 hrs for HSA. Subsequently, confirmatory assays were performed as 
described below, to assess the formation of amyloid aggregates.  
 
     3.2 Confirmatory assays of BSA and HSA amyloid aggregation 
     3.2.1 BSA and HSA amyloid aggregation detected by Thioflavin T dye binding Assay:  
     Increase in ThT emission fluorescence intensity at 485 nm when excited at 450 nm usually occurs 
when ThT binds to amyloid aggregates.  After incubation under fibrillization conditions, the ThT 
fluorescence emission intensity for BSA and HSA amyloid aggregates showed over 19 fold and 11 
fold increase respectively (Tables 2 & 3). This strongly suggests that BSA and HSA proteins have 
undergone amyloid conversion. 
 
Table 2: Thioflavin-T fluorescence intensity (AU) at 485 nm for BSA  
Blank (pH 7.4 buffer) BSA amyloid aggregates Fold increase 
148.7 2943.8 19.7 
 
Table 3: Thioflavin-T fluorescence intensity (AU) at 485 nm for HSA 
Blank (pH 7.4 buffer) HSA amyloid aggregates Fold increase 
226.6 2575.7 11.3 
 
ThT Excitation and Emission spectra for BSA and HSA fibrillization: ThT free dye normally 
shows excitation maximum at 385 nm and emission maximum at 445 (LeVine, 1993). However, 
when Th-T binds with amyloid aggregates, it shows fluorescence excitation maximum at 450 nm 
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and emission maximum at 445nm. The obtained BSA aggregates showed ThT excitation maximum 
λmax at 444 nm and emission maximum λmax at 494 nm whereas the HSA aggregates showed 
excitation maximum λmax at 450 and emission maximum λmax at 496 nm (Figures 10 & 11). These 
observations strongly indicate amyloid nature of the aggregated BSA and HSA proteins. 
 
 
 
 
 
 
 
                                     Figure 10: ThT Excitation and Emission spectra for BSA fibrillization 
 
 
 
 
 
 
 
                                 Figure 11: ThT Excitation and Emission spectra for HSA fibrillization 
  
3.2.2. BSA and HSA amyloid aggregation detected by Congo-Red dye (CR) binding Assay:  
When CR binds with amyloids its absorption spectrum shows red-shift in its absorption maximum 
(from around 490 to 540 nm) and higher absorption intensity at 540 nm (Hawe et al., 2008). The 
CR+BSA and CR+HSA aggregates obtained here, exhibited red shift from 490 to 540 nm and higher 
absorption near 540nm as compared with unbound CR spectrum (Figure 12). These results are 
consistent with the presence of amyloid-like nature of the obtained BSA and HSA aggregates. 
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                                   Figure 12: CR absorption spectra for BSA and HSA fibrillization 
 
3.2.3. Intrinsic Tryptophan fluorescence of BSA and HSA amyloid aggregates:  
The BSA and HSA aggregates obtained here showed intrinsic Trp emission maxima λmax at 334nm 
and 332nm as compared with their un-aggregated monomeric BSA and HSA emission maxima λmax 
of 342nm and 340nm respectively (Figure 13). The observed blue shift of ~8 nm in the emission 
maxima are indicative of movement of tryptophan residues to relatively hydrophobic micro 
environment in both BSA and HSA aggregates (Table 4). This data is consistent with an expected 
internalization of any surface Trp residues during amyloid aggregate formation.  
 
 
 
 
 
 
 
                 Figure 13: Intrinsic Tryptophan fluorescence of BSA and HSA amyloid aggregates. 
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  Table 4: Emission maxima (λmax) of BSA and HSA monomers vs amyloid aggregates 
 BSA HSA 
 Monomer Amyloid 
aggregate 
Monomer Amyloid 
aggregate 
λmax 342 nm 334 nm 340 nm 332nm 
 
3.2.4. Assay of self-seeding nature of BSA & HSA amyloid aggregates:  
The ability to self-seed the aggregation of their monomers under optimal conditions distinguishes 
the amyloid aggregates from amorphous aggregates. However, under experimental conditions, to 
visualize the process of seeding, a lag dependent growth of the amyloid is pre-requisite. Any 
reduction in the lag period upon addition of the pre-formed seed is interpreted as successful 
seeding. Previously, it is shown that BSA and HSA amyloid aggregate formation proceeds  without 
any lag phase at 65°C fibrillization temperature (Holm et al., 2007). Therefore, self-seeding ability of 
pre-formed BSA or HSA aggregates could not be monitored at optimal 65°C fibrillization 
temperature. Therefore, we examined a suboptimal fibrillization temperature (40°C) where 
spontaneous aggregation would be negative due to lack of successful oligomeric nuclei formation 
which normally precedes the amyloid aggregates. However, the added pre-formed seed which 
contains pre-formed nuclei may initiate the conversion of the monomers to aggregates and show 
the seeding kinetics even at suboptimal temperatures. Indeed, as per our hypothesis, the BSA 
amyloid aggregates did show self-seeding even at 40°C as observed by increase in ThT fluoresce 
increase and shape of the emission spectrum (Figures 14 & 15). However, under these conditions 
the HSA aggregates did not exhibit self-seeding thereby suggesting of differences between the 
amyloid growth energetics of BSA and HSA proteins (Figures 14 & 15). 
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Figure 14: Assay of self-seeding kinetics for BSA and HSA aggregation at suboptimal 
temperature (40°C). 
     
 
 
      
 
 
 
 
 
Figure 15: Assay of amyloid-like emission spectra of BSA and HSA samples after self-
seeding kinetics shown in figure 14. 
 
 
3.3 Comparative stability of BSA and HSA amyloid aggregates    
3.3.1 Detergent stability by Semi-denaturing detergent agarose gel electrophoresis:          
Protein amyloid aggregates show increased stability against denaturants (eg. Urea) and ionic 
detergents (eg. SDS & sodium lauroyl sarcosinate i.e. Sarkosyl) when compared with amorphous 
aggregates. To compare the stabilities of the BSA and HSA amyloid aggregates, we investigated their 
resistance to 1% sarkosyl at room temperature using SDD-AGE. As shown in Figure 16, both the HSA 
and BSA aggregates exhibited higher molecular weight species even after sarkosyl treatment 
indicating their resistance against dis-aggregation of sarkosyl. 
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                                     Figure 16: SDD-AGE analysis of HSA and BSA aggregates 
Whereas, the BSA amyloid aggregate showed large smear much above the band of its monomer, the 
HSA amyloid aggregate failed even to enter the gel indicating a very large size. Thus, HSA and BSA 
amyloid aggregates differ significantly with regards to the sizes of their sarkosyl stable species. Using 
calibration curve generated by relative mobility of known proteins, it was estimated that the 
sarkosyl-stable species of BSA and HSA amyloid aggregates were about 995 kDa and 6084 kDa size 
and composed of about 15 and 90 monomers respectively (Tables 5 & 6). In addition, this observed 
sarkosyl stability strongly supports amyloid nature of these BSA & HSA aggregates.  
 Table 5.  Relative mobility of molecular weight markers on SDD-AGE 
 Molecular 
Weight (kDa) 
Distance 
moved (cm) 
Gel front 
(cm) 
Relative 
mobility 
BSA soluble 66 4.7 7.1 0.661 
HSA soluble 67 4.5 7.1 0.633 
Lysozyme 14 6.1 7.1 0.859 
 
Table 6. Estimated mol. wt. of sarkosyl-stable BSA and HSA amyloid aggregate species 
 Distance 
moved 
(cm) 
Gel 
front 
(cm) 
Relative 
mobility 
Calculated 
molecular 
Weight 
(kDa) 
Calculated 
no. of 
monomers 
associated 
BSA 
aggregate 
2.1 7.1 0.295 995.47  15 
HSA 
aggregate 
0.4 7.1 0.056 6084.29  90 
 
1.5 % Agarose gel 
Left to Right 
Lane 1 – Lysozyme + BSA monomer 
Lane 2 - HSA aggregate (240µg) 
Lane 3 - HSA monomer (70µg) 
Lane 4 – BSA aggregate (200µg) 
Lane 5 – BSA monomer (80µg)  
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3.3.2 The stability of BSA and HSA amyloid aggregates at different pH: The pH stability of 
BSA and HSA amyloid aggregates was assayed by ThT fluorescence to check if there are any 
differences in their behaviour.  At the fibrillization pH 7.4 where the aggregates were formed, BSA 
and HSA amyloid aggregates displayed 33.5 and 7.2 fold ThT fluorescence increase respectively 
(Table 7 & 8). When the raw data (Tables 7 & 8;  and Figures 17a & 17b), were carefully analysed, 
we observed that the effect of pH on BSA & HSA amyloid dis-aggregation was similar on all pH 
values except for pH 6.0 & 8.0 (Table 9). At pH 6.0 and 8.0, the BSA amyloid aggregates were found 
to be over 16-20% more stable than HSA amyloid aggregates as seen by retention of higher ThT 
fluorescence (Table 9).  
 
       Table 7: ThT fluorescence emission intensity (AU) at 485 nm for BSA amyloid aggregates 
incubated at different pH  
 
pH Blank (Buffer) BSA aggregates Fold increase 
pH 2.0 174 1736.6 9.9 
pH 4.0 174 2237.0 12.8 
pH 6.0 174 2573.7 14.7 
pH 8.0 174 4789.6 27.5 
pH 9.0 174 3384.4 19.4 
pH 10.0 174 2838.7 16.3 
pH 7.4 174 5844.1 33.5 
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Table 8. ThT fluorescence emission intensity (AU) at 485 nm for HSA amyloid aggregates           
incubated at different pH 
 
pH Blank (Buffer) HSA aggregates Fold increase 
pH 2.0 224.7 519.8 2.3 
pH 4.0 224.7 646.0 2.8 
pH 6.0 224.7 603.4 2.6 
pH 8.0 224.7 1069.9 4.7 
pH 9.0 224.7 1041.1 4.6 
pH 10.0 224.7 843.7 3.7 
pH 7.4 224.7 1613.8 7.2 
  
  
 
                   
   
 
 
 
 
 
 
 
    Figure 17. (a) ThT Emission and Excitation spectra of BSA amyloid aggregates at different pH. 
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      Figure 17. (b) ThT Emission and Excitation spectra of HSA amyloid aggregates at different pH. 
  
  Table 9: Comparative pH stabilities of BSA and HSA amyloid aggregates 
pH  Residual ThT fluorescence 
of BSA (%) 
 Residual ThT fluorescence 
of HSA (%) 
7.4 100% 100% 
2.0 27.5% 21.2% 
4.0 36.3% 33.3% 
6.0 43.3% 27.2% 
8.0 81.4% 60.8% 
9.0 56.6% 58.7% 
10.0 46.9% 44.5% 
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3.3.3 Comparative stabilities of BSA and HSA amyloid aggregates at pH 6.0 and 40°C:  
The pre-formed aggregates of BSA & HSA at pH 7.4 were incubated at pH 6.0 at 40 °C and their 
stability under these conditions was assessed by ThT fluorescence. Following the incubation, 
amyloid aggregates were ultra-centrifuged at 40,100 x g at 4°C for 35 mins and level of ThT 
fluorescence was measured in the supernatant versus the pellet (The pellet was first re-suspended 
in the same volume of fresh pH 6.0 buffer). Furthermore, estimation of protein concentration by 
Bradford reagent and SDS-PAGE were also used to examine the level of protein precipitation by 
ultracentrifugation. It would be expected that if the amyloid is not fully stable under a condition it 
would dis-aggregate and partition more into the supernatant fractions after ultra-centrifugation. 
Alternatively, if the aggregates become larger more amyloid would be expected to partition into the 
pellet fractions. Indeed, by all the examined parameters [eg. ThT fluorescence (Table 10, 11, & 12, 
and Figures 18 & 19), Bradford assay (Table 13 & 14) or SDS-PAGE (Figure 20)], it was evident that 
both BSA and HSA amyloid aggregates increase in size when transferred from pH 7.4 to pH 6.0.  But 
the extent of size increase is more in BSA than HSA amyloid aggregates. 
 
Table 10. ThT Fluorescence intensity of BSA aggregates (pH 6.0, 40oC) after ultra-centrifugation  
 Blank Protein Fold increase 
   pH7.4 Supernatant 204.5 5802.3 28.3 
         pH7.4 Pellet 204.5 434.1 2.1 
pH6.0 Supernatant 149.4 2429.5 16.2 
pH6.0 Pellet 149.4 988.7 6.6 
 
 
Table 11. ThT Fluorescence intensity of HSA aggregates (pH 6.0, 40oC) after ultra-centrifugation  
 Blank Protein Fold increase 
pH7.4 Supernatant 217.6 491.1 2.2 
pH7.4 Pellet 217.6 806.2 3.7 
pH6.0 Supernatant 156.0 261.8 1.6 
pH6.0 Pellet 156.0 556.6 3.5 
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Figure 18. Residual emission and excitation spectra of BSA aggregates after incubation at pH 6.0 &  
                  40oC 
 
Figure 19. Residual emission and excitation spectra of HSA aggregates after incubation at pH 6.0 
&    40oC 
 
   Table 12. Residual Th-T fluorescence (%) of BSA and HSA amyloid aggregates after ultra-
centrifugation 
pH BSA  ThT fluorescence HSA  ThT fluorescence 
 Supernatant Pellet Supernatant Pellet 
7.4 96% 4% 32% 68% 
6.0 & 40oC 73% 27% 21% 79% 
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In addition to the increase in ThT fluorescence in the pellet fractions, when shifted from pH 7.4 to 
pH 6.0, concomitant increase in relative protein content was also observed in the pellet fractions in 
both HSA and BSA amyloid aggregates (Table 13). 
 
Table 13. Relative fractionation of the HSA/BSA aggregates into pellet or supernatant assayed  
                  by Bradford assay 
 
Sample 
 
Pellet/Supernatant at pH 7.4 
 
Pellet/Supernatant  at pH6.0 
 
BSA amyloid aggregates 
 
0.4 
 
 
0.6 
 
HSA amyloid aggregates 
 
1.5 
 
3.8 
 
 
                 1     2    3   4   5   6   7   8    9  10 
 
 
 
 
 
  
     Figure 20: SDS-PAGE of BSA amyloid aggregate of supernatant and pellet at pH7.4 and pH6.0 
 
 
3.4. Conjugation using free cysteine to obtain homo-dimer of BSA and HSA and 
examination of amyloid formation by the dimer molecules. 
 
3.4.1 Determination of number of free cysteine by Ellman’s reagent assay: 
In order to dimerize the BSA or HSA molecules via disulphide linkage, the availability of the one free 
cysteine residue needed to be confirmed. This estimation of the free cysteine was carried out using 
Ellman’s reagent assay using Β-mercaptoethanol and Lysozyme (which has no free cysteine) as a 
positive and negative controls respectively (Table 14). BSA and HSA exhibited 1.1 and 0.50 free 
 
7.5% gel 
Left to Right 
Lane 1, 2- Supernatant pH 7.4 (R and NR) 
Lane 3, 4- Pellet pH 7.4 (R and NR)  
Lane 5- Marker 
Lane 6, 7- Supernatant pH 6.0 (R and NR) 
Lane 8, 9- Pellet pH6.0 (R and NR) 
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sulfhydryl group per molecule respectively thus these proteins could be used for conjugation via 
disulphide bond formation. 
Table 14. Estimation of number of free sulfhydryl groups per protein molecule  
Concentration 
of the sample 
Estimated no. of free 
sulphydryl group/mol. 
 
Published no. of free – SH 
group 
β- mercaptoethanol (0.25 mM) 1.1 1.0 
HSA (0.10 mM) 1.01 1.0 
BSA (0.15 mM) 0.50 1.0 
Lysozyme (0.07 mM) 0.15 0.0 
   
3.4.2 Disulphide linked homo-dimerization of BSA and HSA: For the conjugation, a reaction 
mixture containing 8M urea, 25mM/100mM Hydrogen peroxide, 0.15mM BSA/HSA was prepared in 
reaction buffer (50mM Gly-HCL + 50mM NaCl). The 8M urea was used for exposing out the one free 
cysteine which is present in the 10 Å deep crevice. Hydrogen peroxide was used for the oxidation of 
disulphide bonds. In figure 21, lane 1 and 3 showed BSA dimer bands howerever, the ratio of dimer 
to monomer was ~ 1:4 showing that dimerization was an inefficient process. Also, increasing the 
H2O2 concentration from 25 mM to even 100 mM did not increase the level of dimer formation. In 
figure 22, lane 4 and 6 showed HSA dimer bands and the ratio of dimer to monomer was ~ 2:3. The 
only very minute levels of dimer seen in lanes 2 & 8 show that both urea and H2O2 together are 
required for efficient dimerization. 
 
                                  1                2            3            
          10% gel 
Left to Right 
Lane 1- BSA + Urea + H2O2 (25mM) (NR) 
Lane 3- BSA + Urea + H2O2 (100mM) (NR) 
 
 
                     Figure 21: H2O2 induced dimerization of BSA examined by SDS-PAGE. 
 
 
36 
 
            1        2       3      4      5        6        7      8                    
10% gel      
Left to Right 
Lane 1, 2- HSA + Urea (R and NR) 
   Lane 3, 4- HSA+Urea+H2O2 (25mM) (R and NR) 
   Lane 5, 6- HSA+Urea+H2O2 (100mM) (R and NR)  
   Lane 7, 8- HSA+ H2O2 (100mM) (R and NR)  
 
                    Figure 22: H2O2 induced dimerization of HSA examined by SDS-PAGE. 
 
 3.4.3 Purification of the homo-dimer molecules of HSA/BSA by size exclusion 
chromatography (SEC)   
As the dimerization of HSA/BSA was far less than the expected 100%, thus the dimers needed to be 
purified out from the monomers prior to the assay of their amyloid forming capabilities. As the 
monomers and dimers differ by about 66 kDa, the purification was attempted by SEC using Superose 
6 column (10/300 GL and exclusion limit is 4x107) on FPLC (ÄKTA™FPLC™) system. Size of fractions 
collected were 1ml and 250µl respectively in cases of BSA and HSA. In figure 23 (a), which shows 
elution profile for HSA, two peaks were obtained for which the figure 23 (b) shows estimation of 
purity by SDS-PAGE. As expected, the first peak fractions contained predominantly dimer molecules 
while the second peak fractions showed mostly monomers. As shown in figure 24 (a & b), results 
similar to as described above for BSA were also obtained for BSA dimer purification.  The fractions 
containing predominantly dimers for both HSA/BSA were pooled and further analysed for amyloid 
formation ability. 
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                    Figure 23. (a) SEC Chromatogram of HSA monomer and dimer purification                                   
 
                                              *   *   *                        #   #   #  
 
                                                                10% gel 
 
                          
            
 
      Figure 23 (b).  Analysis of purity of fractions on SDS-PAGE after gel filtration from figure 23(a).     
     
                        
                   Figure 24. (a) SEC chromatogram of BSA monomer and dimer purification 
  1      2      3       4     5       6      7      8      9     10 
   
       
   #     *  
* 
 # 
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                                                                                                                                   10% gel 
 
      Figure 24. (b) Analysis of purity of fractions on SDS-PAGE after gel filtration from figure 24(a).         
 
3.4.4 HSA-dimer amyloid fibrillization and its confirmatory assays 
     After the fractions containing HSA-dimer were obtained by SEC, ammonium sulphate precipitation 
was performed to increase the protein concentration. Obtained pellet was dissolved in fibrillization 
buffer (10mM sodium phosphate containing 50mM NaCl pH 7.4) and incubated for 52 hrs at 65oC. 
Following the incubation, ThT binding was examined by measuring its fluorescence emission 
intensity. We found that the HSA-dimer aggregates were showing over 10.8 fold increase strongly 
suggesting of amyloid-like nature (Table 15). This indicates that HSA in a dimer form have 
undergone amyloid conversion.  
 
                      Table 15: Thioflavin-T fluorescence intensity (AU) at 485 nm for HSA-dimer 
Blank (pH 7.4 buffer) HSA-dimer amyloid Fold increase 
215.56 2334.8 10.8 
 
     1     2      3      4    5      6    7     8      9     10 *           * 
            
#  #  #  
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In addition, the obtained HSA-dimer aggregates were showing ThT excitation maximum λmax at 440 
nm and emission maximum λmax at 496 nm, consistent with as expected upon binding of ThT to 
amyloid aggregates (Figures 25).  
                         Figure 25: ThT Excitation and Emission spectrum of HSA-dimer fibrillization 
 
Furthermore, we checked whether these HSA dimer aggregates bind to Congo red (CR). When CR 
binds to amyloids its absorption spectrum shows red-shift in its absorption maximum (from around 
490 to 540 nm) and higher absorption intensity at 540 nm (Hawe et al., 2008). The CR+HSA dimer 
aggregates obtained here, exhibited red shift from 490 to 540 nm and higher absorption near 
540nm as compared with unbound CR spectrum (Figure 26). These results are consistent with the 
presence of amyloid-like nature of the obtained HSA-dimer aggregates. 
 
                    
                    Figure 26: Absorption spectra of CR in presence of HSA-dimer aggregates. 
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The observed ability of HSA homo-dimer to form amyloid similar to its monomer opens the possibility 
that another therapeutic protein or peptide may be conjugated with HSA and hetero-dimer may be 
converted to amyloid form. This may find potential applications in therapeutic strategies where 
circulatory life of a protein/peptide needs to be increased.
41 
 
CHAPTER IV 
CONCLUSION 
 
Here we succeeded in comparative analysis of properties of HSA and BSA amyloid aggregates. First, 
amyloid aggregates were induced to form and confirmatory assays were performed to ascertain 
their amyloid conformation. Interestingly, it was found that the HSA amyloid aggregates are bigger 
in size and more Sarkosyl detergent stable than the BSA amyloid aggregates despite the high 
sequence similarity between the two proteins. The BSA amyloid aggregates showed 15-20% more 
stability at pH 6.0 and 8.0 as compared to the HSA amyloid aggregates. At other pH values BSA and 
HSA amyloid aggregates were found to show similar stabilities. When shifted from the fibrillization 
pH 7.4 to 6.0 at 40°C, both BSA and HSA amyloid aggregates exhibited increase in the aggregate 
sizes. When we examined the self-seeding ability of BSA & HSA aggregates towards their 
monomers, a marked difference was observed between the two amyloids. Seeding ability was 
assayed at a suboptimal temperature (40°C) due to lack of lag period (which is pre-requisite to 
monitor seeding) in the fibrillization at the optimal temperature (65°C). Whereas the BSA amyloid 
aggregates exhibited self-seeding at the suboptimal temperature assayed, the HSA amyloid 
aggregates could not self-seed under the same conditions tested. This further suggests of the 
presence of conformational differences between the HSA and BSA amyloid aggregates. 
Several therapeutic proteins have been previously conjugated to HSA in order to increase their 
circulatory life and hence their therapeutic duration. As the HSA amyloid aggregates are shown to 
be non-cytotoxic to cell cultures, we hypothesized that use of amyloid form of HSA conjugated with 
a therapeutic protein may further increase the circulatory life of the therapeutic protein since 
amyloid structures are relatively stable to clearance. As a step in this direction, and to provide proof 
of the principle and feasibility, we succeeded here in conjugating HSA with another HSA molecule 
via a disulphide linkage and further showed that indeed the dimers retains amyloid forming 
capabilities alike its monomers. Further studies in this direction, in future, could examine and 
establish the therapeutic usage of an amyloid form a HSA-therapeutic protein heterodimer.  
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